NOVOB80.BK Novo Nordisk A/S
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- 2.87%
- Fundamental score
- -
Is NOVOB80.BK undervalued?
Graham numberThe Graham number of Novo Nordisk A/S cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Novo Nordisk A/S fundamental analysis
No fundamental analysis for Novo Nordisk A/S yet.
Novo Nordisk A/S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone repla…
Full company profileFinancial statements of Novo Nordisk A/S are not available yet.
Novo Nordisk A/S dividends
Novo Nordisk A/S has not paid dividends in the last 3 fiscal years.
Who owns Novo Nordisk A/S
Ownership data of Novo Nordisk A/S is not available yet.
Novo Nordisk A/S company profile
- Company name
- Novo Nordisk A/S
- Ticker
- NOVOB80.BK
- Exchange
- Thailand Exchange
- Sector
- -
- Industry
- -
- Employees
- 68,794
- Fiscal year end
- December
- Address
- Novo Alle 1, Bagsvaerd, Denmark, 2880
- Phone
- 45 44 44 88 88
- Website
- novonordisk.com
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S management
10- Mr. Karsten Munk KnudsenExecutive VP, CFO & Member of the Management Board · born 1971
- Mr. Maziar Mike Doustdar B.A.President, CEO & Member of the Management Board · born 1970
- Dr. Martin Holst LangeEVP of R&D, Chief Scientific Officer and Member of the Management Board · born 1970
- Ms. Tania SabroeEVP of People, Organisation and Corporate Affairs & Member of Management Board · born 1977
- Ms. Thilde Hummel BogebjergExecutive VP of Enterprise IT & Quality and Member of Management Board · born 1982
- Mr. Michael NovodSenior VP & Head of Investor Relations · born 1979
- Mr. Robin EversSenior Vice President of Medical Affairs, Regulatory and Safety · born 1970
- Ms. Xia-Ping ZhouSenior VP & President of China
- Frederik KierSenior Vice President of Global Obesity Unit
- Mads Frederik RasmussenSenior VP & Head of Clinical Drug Development